DE69939732D1 - Apo-2 ligand - Google Patents

Apo-2 ligand

Info

Publication number
DE69939732D1
DE69939732D1 DE69939732T DE69939732T DE69939732D1 DE 69939732 D1 DE69939732 D1 DE 69939732D1 DE 69939732 T DE69939732 T DE 69939732T DE 69939732 T DE69939732 T DE 69939732T DE 69939732 D1 DE69939732 D1 DE 69939732D1
Authority
DE
Germany
Prior art keywords
ligand
apo
antibodies
believed
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69939732T
Other languages
English (en)
Inventor
Avi J Ashkenazi
Robert F Kelley
Mark T O'connel
Robert M Pitti
Ralph H Schwall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE69939732D1 publication Critical patent/DE69939732D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
DE69939732T 1998-01-15 1999-01-15 Apo-2 ligand Expired - Lifetime DE69939732D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US788698A 1998-01-15 1998-01-15
US6053398A 1998-04-15 1998-04-15
PCT/US1999/001039 WO1999036535A1 (en) 1998-01-15 1999-01-15 Apo-2 ligand

Publications (1)

Publication Number Publication Date
DE69939732D1 true DE69939732D1 (de) 2008-11-27

Family

ID=26677483

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69939732T Expired - Lifetime DE69939732D1 (de) 1998-01-15 1999-01-15 Apo-2 ligand

Country Status (13)

Country Link
US (1) US6740739B1 (de)
EP (2) EP1045906B1 (de)
JP (2) JP2002508962A (de)
AT (1) ATE411385T1 (de)
AU (1) AU2325199A (de)
CA (1) CA2318029C (de)
CY (1) CY1108681T1 (de)
DE (1) DE69939732D1 (de)
DK (1) DK1045906T3 (de)
ES (1) ES2316182T3 (de)
HK (1) HK1032603A1 (de)
PT (1) PT1045906E (de)
WO (1) WO1999036535A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
US20040048340A1 (en) * 1996-03-14 2004-03-11 Human Genome Sciences, Inc. Apoptosis inducing molecule I
EP1870464A3 (de) * 1999-06-02 2008-03-12 Genentech, Inc. Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
WO2001000832A1 (en) 1999-06-28 2001-01-04 Genentech, Inc. Methods for making apo-2 ligand using divalent metal ions
JP2005508162A (ja) * 2001-10-02 2005-03-31 ジェネンテック・インコーポレーテッド Ａｐｏ−２リガンド変異体とその使用法
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
ES2351786T3 (es) 2001-11-13 2011-02-10 Genentech, Inc. Formulaciones con ligando apo2/trail y usos de las mismas.
CN1313611C (zh) * 2002-02-22 2007-05-02 中国人民解放军第二军医大学 新型肿瘤凋亡素2配体基因、其表达的肿瘤凋亡素及其制法
WO2004001009A2 (en) * 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
GB0328261D0 (en) 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
US20080242603A1 (en) * 2004-02-20 2008-10-02 Yan Wang Novel Apo2L and IL-24 Polypeptides, Polynucleotides, and Methods of Their Use
AU2012200601B2 (en) * 2004-08-06 2012-10-11 Genentech, Inc. Assays and methods using biomarkers
BRPI0513665A (pt) 2004-08-06 2008-05-13 Genentech Inc método de previsão da sensibilidade, métodos de indução da apoptose, método de tratamento de disfunção em mamìferos, método de previsão da sensibilidade e método de tratamento de cáncer do cólon ou colo-retal em mamìferos
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US20100150931A1 (en) * 2006-11-22 2010-06-17 Centre Hospitalier De L'universite De Montreal Novel receptor for cd40l and uses thereof
GB0724532D0 (en) * 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
WO2011043835A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that bind il-23r
US9388230B2 (en) 2010-09-28 2016-07-12 Kahr Medical(2005) Ltd Compositions and methods for treatment of hematological malignancies
CA2834776A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
CN103534273B (zh) 2011-09-16 2020-05-12 北京沙东生物技术有限公司 环化变构trail/apo2l及其编码基因与应用
EP2684896A1 (de) * 2012-07-09 2014-01-15 International-Drug-Development-Biotech Antikörper gegen die DR5-Familie, bispezifische oder multivalente Antikörper gegen die DR5-Familie und Verfahren zu deren Verwendung
US20160067337A1 (en) 2013-03-14 2016-03-10 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
US9914761B2 (en) 2014-07-10 2018-03-13 Washington University Oligomers for TNF superfamily inhibition
CA3007033A1 (en) 2015-12-01 2017-06-08 Genmab B.V. Anti-dr5 antibodies and methods of use thereof
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
CN110536693B (zh) 2017-01-05 2023-12-22 卡尔医学有限公司 Pd1-41bbl融合蛋白及使用其的方法
KR102581439B1 (ko) 2017-01-05 2023-09-21 카 메디컬 리미티드 Sirp알파-41bbl 융합 단백질 및 이의 이용 방법
WO2018127916A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
IL75318A (en) 1984-05-31 1994-08-26 Genentech Inc Recombinant human memotoxin and methods for its recombinant production
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
CA1338518C (en) 1987-09-23 1996-08-13 Joyce M. Zarling Antibody heteroconjugates for the killing of hiv-infected cells
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
EP0321196A3 (de) 1987-12-18 1990-07-18 Mycogen Plant Science, Inc. Transkriptionsaktivator des 780 T-DNA-Gens
WO1989005859A1 (en) 1987-12-21 1989-06-29 The Upjohn Company Agrobacterium mediated transformation of germinating plant seeds
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
DK168302B1 (da) 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
WO1991008291A2 (en) 1989-11-22 1991-06-13 Genentech, Inc. Latency associated peptide and uses therefor
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
EP0586505A1 (de) 1991-05-14 1994-03-16 Repligen Corporation Heterokonjugat-antikörper zur behandlung von hiv-infektionen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
DE69420137T2 (de) 1993-06-03 1999-12-23 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
US5620889A (en) 1993-10-14 1997-04-15 Immunex Corporation Human anti-Fas IgG1 monoclonal antibodies
WO1995011301A1 (en) 1993-10-19 1995-04-27 The Regents Of The University Of Michigan P53-mediated apoptosis
IL111125A0 (en) 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
EP1666591B1 (de) * 1995-06-29 2011-03-23 Immunex Corporation Cytokin welches Apoptose induziert
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
WO1997046686A2 (en) 1996-06-07 1997-12-11 Amgen Inc. Tumor necrosis factor-related polypeptide
KR20020056565A (ko) 2000-12-29 2002-07-10 황규언 인간유래 세포 소멸 인자와 그 수용체의 결합체인ＴＲＡＩＬ-ｓＤＲ5 결합체의 결정화에 의한 3차원 구조및 ＴＲＡＩＬ 결실 돌연변이 단백질
AU2002258399A1 (en) 2001-02-16 2002-09-19 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer

Also Published As

Publication number Publication date
WO1999036535A9 (en) 2000-03-02
US6740739B1 (en) 2004-05-25
EP2017341A2 (de) 2009-01-21
ATE411385T1 (de) 2008-10-15
DK1045906T3 (da) 2009-02-16
WO1999036535A1 (en) 1999-07-22
EP1045906A1 (de) 2000-10-25
JP2010246560A (ja) 2010-11-04
CA2318029C (en) 2009-05-19
AU2325199A (en) 1999-08-02
CY1108681T1 (el) 2014-04-09
EP1045906B1 (de) 2008-10-15
EP2017341A3 (de) 2009-04-08
ES2316182T3 (es) 2009-04-01
PT1045906E (pt) 2009-01-27
HK1032603A1 (en) 2001-07-27
CA2318029A1 (en) 1999-07-22
JP2002508962A (ja) 2002-03-26

Similar Documents

Publication Publication Date Title
ATE362985T1 (de) Apo-2 ligand
ATE411385T1 (de) Apo-2 ligand
LUC00121I1 (de)
ATE370232T1 (de) Anti-apo-2 antikörper
IS6322A (is) Viðtaki APRIL (BCMA) og notkun hans
IL133311A0 (en) Imidazolyl-cyclic acetals
TW200716745A (en) Anti-TNF antibodies, compositions, methods and uses
DK1032672T3 (da) DNA19355-polypeptid, en tumornekrosefaktor-homolog
DK1009817T3 (da) RTD-receptor
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
ATE236983T1 (de) Durch zelldichte stimulierte protein-tyrosin- phosphatasen
IT8419465A0 (it) Dispersione di carbone in acqua.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition